Regulatory Oversight of Cell Therapy in China: Government's Efforts in Patient Access and Therapeutic Innovation.

Weijia Wu,Yuanyuan Wang,Zhijia Tang,Yuan Gao,Yan Huo

DOI: https://doi.org/10.1016/j.phrs.2020.104889

IF: 10.334

2020-01-01

Pharmacological Research

Abstract:In recent years, remarkable progress has been made in the fundamental research and on clinical development of cell therapy. Although China has launched a series of regulations to establish a proper regulatory framework that facilitates the development of cell therapy products, the regulatory framework has not been able to meet the country's regulatory requirements. This article introduced the development of regulation and current regulatory pathways for cell therapy in China and identified the main challenges in clinical studies. China has recently tightened its policy on cell therapy clinical studies after medical chaos occurred in the area of cell therapy over the past few years. Currently the regulatory jurisdiction between NMPA and NHC are not very clear, especially for clinical somatic cell research, further efforts are necessary to establish a legislative system with a clear and functional regulatory framework for cell therapy.